Back

Rosen Law Firm investigates Disc Medicine claims after 22% stock drop following FDA letter

Verifying
  • Rosen Law Firm is investigating potential securities claims against Disc Medicine.
  • Disc Medicine shares fell 22% on February 13, 2026, after the FDA issued its letter.
  • Rosen Law Firm is preparing a prospective class action for affected investors.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.